2Cleator S, Parton M, Dowsett M. The biology of neoadjuvant chemotherapy for breast cancer [ J]. Endocrine-Related Cancer, 2002,9 ( 3 ) : 183-195.
3Strayer ME, van Adrichem JC, Rutgers E J, et al Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy [ J]. Ned Tijdschr Geneeskd, 2008,152 (46) : 2519-2525.
4Shien T, Akashi-Tanaka S, Miyakawa K, et al. Clinicopathological features of tumors as predictors of the efficacy of primary neoadjurant chemotherapy for operable breast cancer [J]. World J Surg, 2009,33( 1 ) :44-51.
5Fuzhong T, Nan L, Jiajia G,et al. Clinical significance of the relationship between expression of survivin and effects of neoadjuvant chemotherapy in locally advanced breast cancer [ J]. Gan To Kagaku Ryoho ,2008,35 ( 8 ) : 1319-1323.
6Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine year results from National Surgical Adjuvant Breast and Bowel Project B 18 [J]. J Nail Cancer Inst Monogr,2001 (30) :96-102.
7Rastogi P, Anderson SJ, Bear HD ,et al. Preoperative chemotherapy : updates of National Surgical Adjuvant Breast and Bowel Project Protocols B 18 and B 27 [J]. JClin Oncol,2008,26(5) : 778,785.
8van der Hage JA, van de Velde CJH, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer:results from the European organization for research and treatment of cancer trial 10902 [ J]. J Clin Oncol,2001,19(22) :4224-4237.
9Reitsamer R, Peintinger F, Prokop E, et al. Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage Ⅱ and Ⅲ breast cancer [ J ]. Anticancer Drugs,2005,16 ( 8 ) :867-870.
10Kurosumi M. Significance and problems in evaluations of pathological responses to neoadjuvant therapy for breast cancer [ J]. Breast Cancer,2006,13 ( 3 ) :254-259.
